Chlorella Industry Has Acquired FDA GRAS Certification for the Chlorella Powder Product, Unprecedented in Japan for the Exclusively Domestic Cultivation and Production of Chlorella

TOKYO–(BUSINESS WIRE)–Chlorella Industry Co., Ltd. (Minato-ku, Tokyo) has acquired FDA GRAS (Generally Recognized As Safe) certification for the chlorella powder product, unprecedented in Japan for the exclusively domestic cultivation and production of chlorella. Chlorella is a plant-based food source, made up of about 60% protein, and comprised of a variety of vitamins and minerals, chlorophyll … [Read more…]

LUCA Science Raises ¥3.86 Billion ($30.3 Million) in Oversubscribed Series B Financing

Series B co-led by Fast Track Initiative, DCI Partners, and 4BIO Capital Proceeds to accelerate development of LUCA’s novel Mitochondria Isolation Technology (MIT) platform, IND-enabling activities for its in-house pipeline and establish its manufacturing capability TOKYO–(BUSINESS WIRE)–LUCA Science, a global innovator in the development of a novel class of mitochondria biopharmaceutical agents, today announced the … [Read more…]

Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022

STRASBOURG, France–(BUSINESS WIRE)–Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that it presented updated preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting. TG4050 … [Read more…]

Global Mercy™ Begins Local Healthcare Training, Following Historic Week of Events in Dakar

A prestigious award for founder Don Stephens and blessing of the Global Mercy™ add to the launch of a packed training schedule designed to increase healthcare capacity in Africa DAKAR, Senegal–(BUSINESS WIRE)–In the midst of celebrations around the arrival of the Global Mercy™ to Senegal, training has already begun by the crew of the world’s … [Read more…]

Latest Data of InnoCare’s Orelabrutinib for the Treatment of SLE Presented at LBA Session of EULAR 2022

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that Professor Zhanguo Li, the leading PI, has presented latest data of BTK inhibitor orelabrutinib for the treatment of Systemic Lupus Erythematosus (SLE) at the just-concluded EULAR 2022 European Congress of Rheumatology. The abstract was selected as late-breaking oral presentation. Late-breaking Oral Presentation: Orelabrutinib, … [Read more…]

Bigfoot Unity® Demonstrates Strong Glycemic Control Among People with Type 2 Diabetes in Real-World Retrospective Analysis

Data Were Presented at the American Diabetes Association 82nd Scientific Sessions MILPITAS, Calif.–(BUSINESS WIRE)–Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, presented real-world data from its late-breaking abstract presented at the American Diabetes Association 82nd Annual Scientific Sessions. Data from the real-world retrospective analysis suggests that, for … [Read more…]

Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project

Data show MammaPrint® is the first and most comprehensive FDA-cleared test for early breast cancer resulting in the ability to identify women who may be over- or under-treated if treatment decisions relied on the 21-gene assay FLEX Trial continues to support the discovery and development of novel genomic profiles, bringing precision oncology into the clinic … [Read more…]

Updated Data for Janssen’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study evaluating the BCMAxCD3 bispecific antibody, including progression-free survival and subgroup analyses1 Data from MajesTEC-1 study published in The New England Journal of Medicine2 BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and … [Read more…]

NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination with chemoradiation and in the preoperative setting … [Read more…]

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

– CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients – Durable responses seen in both solid tumors and hematologic malignancies in the dose escalation with a 44% disease control rate in the response-evaluable population – Safety and clinical activity from the Phase 1 … [Read more…]